Inactive Instrument

Aceragen, Inc. Stock price Nyse

Equities

ACGN

US00445F1093

Biotechnology & Medical Research

Sales 2021 - Sales 2022 4.86M Capitalization 3.12M
Net income 2021 98M Net income 2022 -23M EV / Sales 2021 * -
Net cash position 2021 * - Net cash position 2022 * - EV / Sales 2022 * -
P/E ratio 2021 *
-
P/E ratio 2022 *
-
Employees 26
Yield 2021 *
-
Yield 2022 *
-
Free-Float 38.12%
More Fundamentals * Assessed data
Dynamic Chart
Aceragen Inc is a clinical-stage biopharmaceutical company. The Company is focused on the clinical development, and commercialization, of drug candidates for rare disease indications characterized by small, well-defined patient populations with serious unmet medical needs. The Company’s pipeline includes ACG-701 to treat cystic fibrosis (CF) pulmonary exacerbations (PEx) and melioidosis, and ACG-801 to treat Farber disease. Its focus is to develop and optimize the commercial value of ACG-701 and ACG-801 for appropriate patients. ACG-701 is an oral, loading dose formulation of sodium fusidate being developed as a potential treatment for PEx associated with cystic fibrosis CF, a factor driving lung function decline in people living with CF. ACG-701 is also being developed for the treatment of melioidosis, a life-threatening infection that can affect numerous organ systems, including the lungs.
More about the company
  1. Stock
  2. Equities
  3. Stock Aceragen, Inc.
  4. Stock Aceragen, Inc. - Nyse